GLP-1 Peptides: Semaglutide, Tirzepatide, and the New Generation

What GLP-1 Is

Glucagon-like peptide-1 (GLP-1) is an incretin hormone produced by L-cells in the small intestine in response to food intake. It has multiple physiological roles: stimulating insulin secretion from the pancreas in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and signaling satiety to the central nervous system.

Because native GLP-1 is rapidly degraded by the enzyme DPP-4 (dipeptidyl peptidase-4), its circulating half-life is only a few minutes. GLP-1 receptor agonists (GLP-1 RAs) are engineered peptides designed to mimic GLP-1's actions while resisting enzymatic degradation, enabling sustained receptor activation.

Semaglutide: Single-Receptor Agonism

Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk. It was designed with structural modifications — including a C18 fatty acid chain attachment — that enable albumin binding in the bloodstream, extending its half-life to approximately one week and enabling once-weekly dosing.

Clinical trials, including the SUSTAIN series for type 2 diabetes and the STEP series for obesity, demonstrated significant reductions in HbA1c, body weight, and in the SUSTAIN-6 cardiovascular outcomes trial, reductions in major adverse cardiovascular events in high-risk patients.

Semaglutide acts exclusively on the GLP-1 receptor. Its effects on weight are substantial compared to earlier GLP-1 RAs but have been exceeded by newer multi-receptor agonists.

Tirzepatide: Dual GLP-1 / GIP Agonism

Tirzepatide (Eli Lilly) is a dual agonist targeting both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is another incretin hormone that potentiates insulin secretion and has receptors in adipose tissue, where it may influence lipid metabolism.

The SURPASS clinical trial program demonstrated that Tirzepatide produced greater weight loss and HbA1c reductions than semaglutide at comparable doses. The SURMOUNT program examined weight management specifically, showing mean weight reductions of approximately 20–22% in participants without diabetes.

The dual-receptor mechanism is thought to provide additive or synergistic effects on energy balance, though the exact contribution of GIP receptor agonism relative to GLP-1 receptor agonism remains a subject of active research.

Retatrutide: Triple-Receptor Agonism

Retatrutide (Eli Lilly, in development as of this writing) represents the next step: a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The addition of glucagon receptor agonism is intended to increase hepatic glucose output, thermogenesis, and energy expenditure — effects that complement the satiety and insulin-related actions of GLP-1 and GIP.

Phase 2 trial data published in 2023 showed mean weight reductions of approximately 24% over 48 weeks, exceeding outcomes seen with dual agonists in matched timeframes. Phase 3 trials were underway or in planning stages at the time of this writing.

Glucagon receptor agonism has historically raised concerns about hyperglycemia, but the glucose-dependent insulin secretion driven by GLP-1 and GIP components appears to offset this risk at the doses studied.

The Evolving Research Landscape

The progression from single to dual to triple incretin receptor agonism represents one of the most rapidly advancing areas in peptide pharmacology. The clinical evidence base for semaglutide is extensive, while tirzepatide has substantial phase 3 data. Retatrutide and other investigational multi-receptor agonists are at earlier stages.

Researchers studying metabolic peptides should note that this category is distinguished from most research peptides by the existence of robust, large-scale clinical trial data — particularly for semaglutide and tirzepatide. The compounds are regulated pharmaceuticals in most jurisdictions.

--- For research use only. Not medical advice.